Ashoo Gupta Biography and Net Worth

Ashoo Gupta is the VP of 4D Molecular Therapeutics. They are 50 years old.

What is Ashoo Gupta's net worth?: The estimated net worth of Ashoo Gupta is at least $424.28 thousand as of December 20th, 2025. Gupta owns 46,218 shares of 4D Molecular Therapeutics stock worth more than $424,281 as of March 24th. This net worth approximation does not reflect any other investments that Gupta may own. Learn More about Ashoo Gupta's net worth.
How do I contact Ashoo Gupta?: The corporate mailing address for Gupta and other 4D Molecular Therapeutics executives is , , . 4D Molecular Therapeutics can also be reached via phone at 510-505-2680 and via email at [email protected]. Learn More on Ashoo Gupta's contact information.
Has Ashoo Gupta been buying or selling shares of 4D Molecular Therapeutics?: Ashoo Gupta has not been actively trading shares of 4D Molecular Therapeutics during the last quarter. Most recently, Ashoo Gupta sold 389 shares of the business's stock in a transaction on Saturday, December 20th. The shares were sold at an average price of $8.68, for a transaction totalling $3,376.52. Following the completion of the sale, the vice president now directly owns 46,218 shares of the company's stock, valued at $401,172.24. Learn More on Ashoo Gupta's trading history.
Who are 4D Molecular Therapeutics' active insiders?: 4D Molecular Therapeutics' insider roster includes Scott Bizily (Insider), Ashoo Gupta (VP), David Kirn (CEO), and David Schaffer (Director). Learn More on 4D Molecular Therapeutics' active insiders.
Are insiders buying or selling shares of 4D Molecular Therapeutics?: During the last twelve months, insiders at the sold shares 7 times. They sold a total of 12,787 shares worth more than $130,612.62. The most recent insider tranaction occured on December, 20th when VP Ashoo Gupta sold 389 shares worth more than $3,376.52. Insiders at 4D Molecular Therapeutics own 9.6% of the company. Learn More about insider trades at 4D Molecular Therapeutics.
Information on this page was last updated on 12/20/2025.

Ashoo Gupta Insider Trading History at 4D Molecular Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/20/2025	Sell	389	$8.68	$3,376.52	46,218

Ashoo Gupta Buying and Selling Activity at 4D Molecular Therapeutics

4D Molecular Therapeutics Company Overview

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Today's Range

Now: $9.18

$8.83

$9.26

50 Day Range

MA: $8.79

$7.55

$10.07

2 Week Range

Now: $9.18

$2.23

$12.34

Volume

769,153 shs

Average Volume

749,578 shs

Market Capitalization

$468.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.99